Abstract
The role of polyunsaturated fatty acids and their metabolites for the cause and treatment of psychotic disorders are widely discussed. The efficacy as an augmenting agent in chronic schizophrenia seems to be small or not present, however epidemiological data, as well as some recent controlled studies in emerging psychosis point towards possible preventive effects of long-chain polyunsaturated fatty acids in early and very early stages of psychotic disorders and some potential secondary or tertiary beneficial long-term effects in later, more chronic stages, in particular for metabolic or extra-pyramidal side effects. In this comprehensive review, we describe the physiology and metabolism of polyunsaturated fatty acids, phospholipases, epidemiological evidence and the effect of these fatty acids on the brain and neurodevelopment. Furthermore, we examine the available evidence in indicated prevention in emerging psychosis, monotherapy, add-on therapy and tolerability. The neuroprotective potential of n-3 LC-PUFAs for indicated prevention, i.e. delaying transition to psychosis in high-risk populations needs to be further explored.
Keywords: Polyunsaturated fatty acids, essential fatty acids, omega-3 fatty acids, prodrome, psychosis, metabolites, psychotic disorders, neurodevelopment, monotherapy, membrane fluidity
Current Pharmaceutical Design
Title: Polyunsaturated Fatty Acids in Emerging Psychosis
Volume: 18 Issue: 4
Author(s): Nilufar Mossaheb, Monika Schloegelhofer, Miriam R. Schaefer, Paolo Fusar-Poli, Stefan Smesny, Pat McGorry, Gregor Berger and G. Paul Amminger
Affiliation:
Keywords: Polyunsaturated fatty acids, essential fatty acids, omega-3 fatty acids, prodrome, psychosis, metabolites, psychotic disorders, neurodevelopment, monotherapy, membrane fluidity
Abstract: The role of polyunsaturated fatty acids and their metabolites for the cause and treatment of psychotic disorders are widely discussed. The efficacy as an augmenting agent in chronic schizophrenia seems to be small or not present, however epidemiological data, as well as some recent controlled studies in emerging psychosis point towards possible preventive effects of long-chain polyunsaturated fatty acids in early and very early stages of psychotic disorders and some potential secondary or tertiary beneficial long-term effects in later, more chronic stages, in particular for metabolic or extra-pyramidal side effects. In this comprehensive review, we describe the physiology and metabolism of polyunsaturated fatty acids, phospholipases, epidemiological evidence and the effect of these fatty acids on the brain and neurodevelopment. Furthermore, we examine the available evidence in indicated prevention in emerging psychosis, monotherapy, add-on therapy and tolerability. The neuroprotective potential of n-3 LC-PUFAs for indicated prevention, i.e. delaying transition to psychosis in high-risk populations needs to be further explored.
Export Options
About this article
Cite this article as:
Mossaheb Nilufar, Schloegelhofer Monika, R. Schaefer Miriam, Fusar-Poli Paolo, Smesny Stefan, McGorry Pat, Berger Gregor and Paul Amminger G., Polyunsaturated Fatty Acids in Emerging Psychosis, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316055
DOI https://dx.doi.org/10.2174/138161212799316055 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential for the Rational Design of Allosteric Modulators of Class C GPCRs
Current Topics in Medicinal Chemistry Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Significance of MRI Guided Focused Ultrasound Thalamotomy for Parkinson’s Disease: A Review
Current Medical Imaging Antipsychotics in Obsessive-Compulsive Disorder
Current Psychiatry Reviews Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry Possible Neuroprotective Strategies for Huntingtons Disease
Current Neuropharmacology Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics
Current Molecular Medicine The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?
Current Drug Targets Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Depot Based Drug Delivery System for the Management of Depression
Current Drug Delivery Central Serotonin2C Receptor: From Physiology to Pathology
Current Topics in Medicinal Chemistry Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors
CNS & Neurological Disorders - Drug Targets Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins
Current Proteomics